Effectiveness of inactivated COVID-19 vaccines in preventing COVID-19-related hospitalization during the Omicron BF.7-predominant epidemic wave in Beijing, China: a cohort study.

Publication date: Sep 17, 2024

To estimate vaccine effectiveness(VE) against COVID-19-related hospitalization for inactivated vaccines during the Omicron BF. 7-predominant epidemic wave in Beijing, China. We recruited a cohort in Beijing on 17 and 18 December 2022, collected status of vaccination and COVID-19-related hospitalization since 1 November 2022 and prospectively followed until 9 January 2023. A Poisson regression model was used to estimate the VE. 16(1. 15%) COVID-19-related hospitalizations were reported in 1391 unvaccinated participants; 7(0. 25%) in 2765 participants with two doses, resulting in a VE of 70. 89%(95% confidence interval[CI] 26. 25 to 87. 73); 32(0. 27%) in 11,846 participants with three doses, with a VE of 65. 25%(95% CI 32. 24 to 81. 83). The VE of three doses remained above 64% at 1 year or more since the last dose. Elderly people aged ≥ 60 years had the highest hospitalization incidence(0. 66%), VE for two doses was 74. 11%(95%CI: - 18. 42 to 94. 34) and VE for three doses was 80. 98%(95%CI:52. 83 to 92. 33). We estimated that vaccination had averted 65,007(95%CI: 12,817 to 97,757) COVID-19-related hospitalizations among people aged ≥ 60 years during the BF. 7-predominant period in Beijing. Inactivated COVID-19 vaccines were effective against COVID-19-related hospitalization, especially for the elderly population who have increased risk of severe disease owing to SARS-CoV-2 infection.

Open Access PDF

Concepts Keywords
Beijing Cohort study
December COVID-19
Hospitalization Hospitalization
Inactivated vaccine
Vaccine effectiveness

Semantics

Type Source Name
disease MESH COVID-19
pathway REACTOME SARS-CoV-2 Infection
disease MESH Long Covid
disease MESH Infectious Diseases
pathway REACTOME Reproduction
drug DRUGBANK Coenzyme M
disease MESH emergency
disease MESH infection
disease MESH death
disease IDO virulence
drug DRUGBANK Ademetionine
drug DRUGBANK Methionine
drug DRUGBANK Ilex paraguariensis leaf
disease IDO history
disease IDO assay
disease MESH sore throat
disease MESH ageusia
disease MESH anosmia
disease IDO process
disease IDO host
disease MESH chronic diseases
disease MESH uncertainty
drug DRUGBANK Trestolone
drug DRUGBANK Methyl isocyanate
disease MESH viral shedding
disease MESH coronavirus infection
disease MESH Influenza
disease MESH complications
disease IDO cell

Original Article

(Visited 1 times, 1 visits today)